[go: up one dir, main page]

MX2021011698A - Moleculas de unión específicas. - Google Patents

Moleculas de unión específicas.

Info

Publication number
MX2021011698A
MX2021011698A MX2021011698A MX2021011698A MX2021011698A MX 2021011698 A MX2021011698 A MX 2021011698A MX 2021011698 A MX2021011698 A MX 2021011698A MX 2021011698 A MX2021011698 A MX 2021011698A MX 2021011698 A MX2021011698 A MX 2021011698A
Authority
MX
Mexico
Prior art keywords
specific binding
binding molecules
variable domains
alpha
beta
Prior art date
Application number
MX2021011698A
Other languages
English (en)
Inventor
Mary Marguerita Connolly
Sara Crespillo Torreño
Richard Suckling
Marcin Dembek
Jose Donoso
Katrin Weiderhold
Andrew Knox
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Publication of MX2021011698A publication Critical patent/MX2021011698A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a moléculas de unión específicas que se unen al péptido GLSPTVWLSV restringido a HLA-A*O2 (SEQ ID NO: 1) derivado de la proteína de envoltura del HBV. Las moléculas de unión especificas pueden comprender dominios variables de TCR alfa y/o beta y pueden comprender mutaciones no naturales dentro de los dominios variables alfa y/o beta con respecto a un TCR nativo. Las moléculas de unión específicas de la invención son particularmente adecuadas para su uso como nuevos reactivos inmunoterapéuticos para el tratamiento de enfermedades infecciosas o malignas.
MX2021011698A 2019-03-28 2020-03-27 Moleculas de unión específicas. MX2021011698A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1904328.0A GB201904328D0 (en) 2019-03-28 2019-03-28 Specific binding molecules
PCT/EP2020/058681 WO2020193745A1 (en) 2019-03-28 2020-03-27 Binding molecules specfic for hbv envelope protein

Publications (1)

Publication Number Publication Date
MX2021011698A true MX2021011698A (es) 2022-01-18

Family

ID=66442860

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011698A MX2021011698A (es) 2019-03-28 2020-03-27 Moleculas de unión específicas.

Country Status (17)

Country Link
US (1) US20220143207A1 (es)
EP (1) EP3947444B1 (es)
JP (1) JP7594542B2 (es)
KR (1) KR20220015376A (es)
CN (1) CN113874393B (es)
AU (1) AU2020247468A1 (es)
BR (1) BR112021019302A2 (es)
CA (1) CA3134692A1 (es)
ES (1) ES3016662T3 (es)
GB (1) GB201904328D0 (es)
IL (1) IL286674A (es)
MA (1) MA55494A (es)
MX (1) MX2021011698A (es)
PH (1) PH12021552308A1 (es)
SG (1) SG11202110386TA (es)
WO (1) WO2020193745A1 (es)
ZA (1) ZA202107221B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
CN119930832A (zh) * 2023-11-02 2025-05-06 北京智仁美博生物科技有限公司 结合HLA-A02/HBsAg复合体的多种抗体及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417324B1 (en) * 2000-04-21 2002-07-09 Tripep Ab Synthetic peptides that bind to the hepatitis B virus core and e antigens
EP0977886A4 (en) 1997-03-07 2002-10-23 Sunol Molecular Corp FUSION PROTEINS, WHICH CONTAIN A BACTERIOPHAGE ENVELOPE PROTEIN AND A SINGLE CHAIN T-CELL RECEPTOR
EP1019439B1 (en) 1997-10-02 2011-11-16 Altor BioScience Corporation Soluble single-chain t-cell receptor proteins
AU5076301A (en) 1999-12-06 2001-07-09 Board Of Trustees Of The University Of Illinois, The High affinity tcr proteins and methods
EP1259601A2 (en) 2000-02-22 2002-11-27 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
NZ531208A (en) 2001-08-31 2005-08-26 Avidex Ltd Multivalent soluble T cell receptor (TCR) complexes
EP1452541B2 (en) * 2001-11-08 2015-06-17 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Hepatitis e virus monoclonal antibodies or the binding fragments of it and the use thereof
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
EP2048159B1 (en) 2002-11-09 2014-01-01 Immunocore Ltd. T cell receptor display
EP1765860B1 (en) * 2004-05-19 2008-12-10 MediGene Ltd. High affinity ny-eso t cell receptor
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
WO2009136874A1 (en) * 2008-05-09 2009-11-12 Agency For Science, Technology And Research Hbv epitope reactive exogenous t cell receptor (tcr) and uses thereof
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
SG177025A1 (en) * 2010-06-21 2012-01-30 Agency Science Tech & Res Hepatitis b virus specific antibody and uses thereof
EP2600898A1 (en) * 2010-08-05 2013-06-12 F.Hoffmann-La Roche Ag Anti-mhc antibody anti-viral cytokine fusion protein
CN102786592A (zh) * 2011-05-17 2012-11-21 傅阳心 Hbv特异性抗体
JP6440259B2 (ja) * 2012-06-11 2018-12-19 シャアメン ユニバーシティ Ｈｂｖ感染及び関連疾患を処置するためのポリペプチド及び抗体
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
CA2924252C (en) * 2013-09-16 2022-01-04 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions
GB201322430D0 (en) * 2013-12-18 2014-02-05 Immunocore Ltd T cell receptors
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
WO2016174652A1 (en) * 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201604468D0 (en) * 2016-03-16 2016-04-27 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
US11186624B2 (en) * 2016-09-23 2021-11-30 Lion Tcr Pte. Ltd. HBV antigen specific binding molecules and fragments thereof
SG11202000027WA (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
KR20200064085A (ko) * 2017-09-07 2020-06-05 큐 바이오파마, 인크. 접합 부위를 갖는 t-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법

Also Published As

Publication number Publication date
CN113874393B (zh) 2025-04-25
BR112021019302A2 (pt) 2021-12-14
CA3134692A1 (en) 2020-10-01
EP3947444B1 (en) 2025-03-05
AU2020247468A1 (en) 2021-11-18
MA55494A (fr) 2022-04-13
NZ781068A (en) 2025-03-28
ZA202107221B (en) 2025-04-30
PH12021552308A1 (en) 2022-07-04
ES3016662T3 (en) 2025-05-09
JP2022526786A (ja) 2022-05-26
KR20220015376A (ko) 2022-02-08
SG11202110386TA (en) 2021-10-28
US20220143207A1 (en) 2022-05-12
IL286674A (en) 2021-12-01
GB201904328D0 (en) 2019-05-15
CN113874393A (zh) 2021-12-31
JP7594542B2 (ja) 2024-12-04
EP3947444A1 (en) 2022-02-09
WO2020193745A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
MX2024001522A (es) Receptores de celulas t.
CO2018011972A2 (es) Receptores de células t
MX395153B (es) Receptores de células t.
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
CL2024003715A1 (es) Proteína de unión multiespecífica que se une a nkg2d, cd33 y cd16; composición; y uso.
CL2024003895A1 (es) Proteínas que se unen a nkg2d, flt3 y cd16; composición farmacéutica; y su uso.
PE20181923A1 (es) Neoantigenos y metodos de su uso
BR112017009177A2 (pt) vacinas terapêuticas contra hpv16
MX2022004906A (es) Moleculas de union especifica.
MX2021011698A (es) Moleculas de unión específicas.
BR112018000660A2 (pt) peptídeos anti-inflamatórios e seu uso
EA201792362A1 (ru) Композиции и способы для лечения целиакии спру
CO2020014681A2 (es) Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
BR112018000655A2 (pt) peptídeos promotores do crescimento e seu uso
MX2022004873A (es) Polipeptidos de tgf-?.
MX2021015501A (es) Anticuerpos y metodos de uso.
WO2021011673A3 (en) Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
CR20190513A (es) Proteínas de unión al antígeno anti-jagged1
MX2021003660A (es) Composicion inyectable.
PE20190967A1 (es) Aislados modificados de streptomyces fungicidicus y su uso
AR099671A1 (es) ANTÍGENO DE INHIBINA a, GEN CODIFICANTE DE INHIBINA a, GEN CODIFICANTE DE PROTEÍNA DE FUSIÓN, PROCESO DE OBTENCIÓN DEL ANTÍGENO DE INHIBINA a, COMPOSICIÓN ANTIGÉNICA, USO DEL ANTÍGENO DE INHIBINA a Y USO DE LA COMPOSICIÓN ANTIGÉNICA
BR112019004337A2 (pt) peptídeo isolado, polipeptídeo isolado, método para modificar um peptídeo, ácido nucleico isolado, construção genética, célula, métodos produção de um agente, de promoção de proliferação celular e de cicatrizar de uma ferida, agente, composição farmacêuticae anticorpo
MX2020009877A (es) Péptidos neutralizantes de miotoxina.
EA202190770A1 (ru) Способ высокопроизводительного скрининга на пептиды с аффинностью к молекулам mhc как лигандов ткр
BR102017001300A2 (pt) peptídeos sintéticos, método e kit para diagnóstico da rinotraqueíte infeciosa bovina, e uso